Ballicules › Drugs › Esketamine
REMS restricted
What it is NMDA receptor antagonist given intranasally; treatment-resistant depression.
Why this one Antidepressant benefit can begin within hours rather than weeks, including in depression with acute suicidal ideation.
What limits it Sedation and dissociation require two hours of monitoring in a REMS-certified setting. Abuse potential; blood pressure rises acutely.
FDA-approved for
treatment-resistant depression (2019) depression with acute suicidality (2020)
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Sedation; dissociation; respiratory depression; abuse and misuse; suicidal thoughts and behaviors — available only through a restricted REMS program with post-dose monitoring.
FDA dosing Population Start Target Max
Treatment-resistant depression (monotherapy or with oral AD) Adults 56 mg twice weekly (induction wk 1-4) 56-84 mg weekly (wk 5-8), then q2wk or weekly 84 mg
Depressive symptoms in MDD with acute suicidal ideation/behavior (with oral AD) Adults 84 mg twice weekly x4 wk (may reduce to 56 mg BIW) 84 mg twice weekly 84 mg
Renal Undefined
Hepatic Undefined
Device delivers 28 mg; use 2 devices (56 mg) or 3 devices (84 mg) with 5-minute rest between devices
Instructions Intranasal use only under direct healthcare-provider supervision Assess BP before and ~40 min after dosing; observe patient at least 2 hours Avoid food 2 h before and liquids 30 min before administration Nasal corticosteroid/decongestant at least 1 h before Do not drive/operate machinery until next day after restful sleep
Contraindications Aneurysmal vascular disease (thoracic/abdominal aorta, intracranial, peripheral) or arteriovenous malformation History of intracerebral hemorrhage
Cautions MAOIs due to risk of serotonin syndrome Sedation/loss of consciousness Dissociation and perceptual changes Respiratory depression Increases in blood pressure Cognitive impairment Impaired ability to drive/operate machinery Ulcerative or interstitial cystitis Abuse and misuse Embryo-fetal toxicity
Adverse reactions Dissociation Dizziness Nausea Sedation Vertigo Hypoesthesia Anxiety Lethargy Blood pressure increased Vomiting Feeling drunk Headache
Pregnancy Not recommended in pregnancy; may cause fetal harm
Lactation Present in human milk; breastfeeding not recommended
⚠ BOXED WARNINGS
Sedation Dissociation Abuse and misuse Suicidal thoughts and behaviors
Cost, est. cash $300–$2,500/month
Generic entry 2030s est.
Classes and tags
Clinical profile
Therapeutic safety burden 4 / 4
Overdose danger 3 / 4
Weight-gain liability 1 / 4
Sedation liability 1 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 2 / 4
Legacy pregnancy category Not assigned — PLLR-era drug
Defining liability Dissociation, sedation and blood-pressure elevation require supervised dosing and observation.
Mechanism of action: Esketamine ballicule
Open Esketamine in the interactive console ↗
Memory aids: mascots and interaction avatars
“Spray gato”
Open Esketamine in the interactive console ↗